Cleveland BioLabs, Inc. (CBLI) Receives an Increase in DoD Protectan CBLB502 Contract
More News related to CBLI
- Cleveland BioLabs to Present at Roth Capital Partners 22nd Annual OC Growth Stock Conference
- Cleveland BioLabs Announces Annual Meeting
- Unusual 11 Mid-Day Movers 2/26: RST, CKR, MPET, WAVX, DECK Higher; PMFG, RMTI, CBLI, ORCC Lower
- Morning Movers 2/26: CKR, RST, CHCI, HBIO, DECK Higher; RMTI, PMFG, CBLI, DAIO, WTW, ATHN Lower
- Cleveland BioLabs (CBLI) to Raise $5M in Private Placement with Institutional Investors
Cleveland BioLabs, Inc. (Nasdaq: CBLI) announced today that the Chemical Biological Medical Systems Medical Identification and Treatment Systems Joint Program Executive Office (CBMS-MITS JPEO) of The Department of Defense (DoD) incresed the ongoing contract for the developmental studies related to Protectan CBLB502. The contract, awarded in April 2008, will increase from $8.86 million to $9.59 million.
Related Categories
Corporate NewsStocks Mentioned
-0.03Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
